Predict your next investment

Corporation
HEALTHCARE | Medical Devices & Equipment / Therapeutic Devices
glaukos.com

See what CB Insights has to offer

Founded Year

1998

Stage

PIPE | IPO

Total Raised

$124M

Market Cap

3.41B

Stock Price

53.94

Revenue

$0000 

About Glaukos

Glaukos (NYSE: GKOS) is an ophthalmic medical technology company focused on the development and commercialization of products and procedures to transform the treatment of glaucoma, one of the leading causes of blindness. Glaukos developed Micro-Invasive Glaucoma Surgery, or MIGS, in order to improve the traditional glaucoma treatment and management paradigm.

Glaukos Headquarter Location

229 Avenida Fabricante

San Clemente, California, 92672,

United States

949-367-9600

Latest Glaukos News

Glaukos, Ivantis settle patent dispute over Hydrus Microstent

Sep 16, 2021

Glaukos and Ivantis will submit a joint request to terminate the pending legal dispute, and dismiss it upon receiving the first upfront payment Glaukos, Ivantis to settle patent dispute. Glaukos has reached an agreement with California-based ophthalmic device maker Ivantis to resolve a patent infringement lawsuit concerning the latter’s Hydrus Microstent. The patent infringement case with the US District Court for the Central District of California was lodged in April 2018. Under the settlement agreement, Glaukos is expected to receive $60m, half of which ($30m) is expected by the end of this year, and the remaining ($30m) by end of 2022. The company is expected to receive a 10% royalty through April 2025, based on sales of the Ivantis’ Hydrus Microstent in the US, along with sales outside the US. Glaukos president and chief executive officer Thomas Burns said: “Since our founding in 1998, Glaukos has invested considerable time and resources to develop novel technologies that have pioneered an entirely new treatment category for glaucoma surgeons and their patients. “We remain confident in the strength of our robust intellectual property portfolio and believe this settlement allows us to focus our full attention and resources on executing our long-term growth strategy by bringing transformative new technologies to the market for the benefit of patients worldwide.” In relation with the settlement, both the parties have agreed on mutual licenses and covenants, and to stop filing lawsuits pertaining Hydrus and iStent technologies. The companies are anticipated to submit a joint request to terminate the pending legal dispute, and dismiss it upon receiving the first upfront payment. Glaukos is a US-based ophthalmic technology and pharmaceutical firm, focused on advanced therapies for the treatment of glaucoma, corneal disorders and retinal diseases, The company is specialised in micro-invasive glaucoma surgery (MIGS), to improve the traditional glaucoma treatment and management paradigm. It is engaged in building a complete portfolio of micro-scale surgical and pharmaceutical therapies, leveraging its platform technology. Glaukos has rolled out its first MIGS device iStent in 2012, next-generation iStent inject device in 2018, and iStent inject W device in 2020, in the US. Do you have interesting content to share with us? Enter your email address so we can get in touch. Related Article

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing Glaukos

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Glaukos is included in 3 Expert Collections, including Eye Health.

E

Eye Health

711 items

D

Diabetes

1,749 items

M

Medical Devices

297 items

Companies that received PMA from the FDA since 2014. Companies tagged as #FDAPMA

Glaukos Patents

Glaukos has filed 94 patents.

The 3 most popular patent topics include:

  • Diseases of the eye and adnexa
  • Ophthalmology
  • Eye surgery
patents chart

Application Date

Grant Date

Title

Related Topics

Status

9/28/2018

9/14/2021

Diseases of the eye and adnexa, Ophthalmology, Eye surgery, Glaucoma, Surgical removal procedures

Grant

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

Application Date

9/28/2018

00/00/0000

00/00/0000

00/00/0000

00/00/0000

Grant Date

9/14/2021

00/00/0000

00/00/0000

00/00/0000

00/00/0000

Title

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Related Topics

Diseases of the eye and adnexa, Ophthalmology, Eye surgery, Glaucoma, Surgical removal procedures

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Status

Grant

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Glaukos Web Traffic

Rank
Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

Glaukos Rank

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.